Plant Name: Delphinium brownii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.322E-12 | 1.808E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.457E-12 | 1.941E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.544E-10 | 2.586E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, NOX4, PTGS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.196E-10 | 9.798E-07 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 4.075E-09 | 2.862E-06 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.892E-08 | 8.958E-06 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.516E-07 | 4.926E-05 | CYP1A2, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.060E-07 | 8.767E-05 | CFTR, HIF1A, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.043E-07 | 2.212E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 9.973E-07 | 2.382E-04 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.242E-06 | 2.787E-04 | AR, CYP19A1, ESR1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.653E-06 | 3.596E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.756E-06 | 3.750E-04 | ABCG2, ACHE, CSNK2A1, ESR1, ESR2, FLT3, MAPT, MCL1, PKM, PTGS2, TP53, TTR, USP2, XDH |
| MF | GO:0005488; binding | GO:0019899; enzyme binding | 2.021E-06 | 4.191E-04 | AR, CFTR, CYP1A1, CYP1A2, CYP3A4, ESR1, ESR2, GSK3B, HIF1A, MAPT, POLB, PTGS2, SYK, TNKS2, TP53, USP2 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.968E-06 | 7.330E-04 | CDK6, CFTR, HIF1A, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.972E-06 | 7.330E-04 | APEX1, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.972E-06 | 7.330E-04 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 5.369E-06 | 9.506E-04 | APEX1, AR, CSNK2A1, CYP2D6, ESR1, ESR2, GSK3B, HIF1A, MAPT, MCL1, NPC1, PTGS2, TNKS, TNKS2, TP53, USP2, XDH |
| BP | GO:0032502; developmental process | GO:0007568; aging | 6.430E-06 | 1.103E-03 | APEX1, CYP1A1, NOX4, POLB, PTGS2, TP53 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 7.475E-06 | 1.262E-03 | AR, CDK6, CSNK2A1, ESR1, FLT3, HIF1A, PTGS2, SYK, THPO, TSHR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 9.869E-06 | 1.640E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.869E-06 | 1.640E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 1.078E-05 | 1.765E-03 | APEX1, CFTR, NOX4, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.190E-05 | 1.864E-03 | CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.190E-05 | 1.864E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.190E-05 | 1.864E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.235E-05 | 1.920E-03 | CYP1A1, HIF1A, NOX4, PKM, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.311E-05 | 2.024E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.727E-05 | 2.558E-03 | GSK3B, MAPT, MCL1, TP53 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.916E-05 | 2.819E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.998E-05 | 2.920E-03 | APEX1, CDK6, CFTR, CYP1B1, PTGS2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 2.152E-05 | 3.104E-03 | CYP1B1, HIF1A, PTGS2 |
| MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 2.216E-05 | 3.159E-03 | AR, CSNK2A1, ESR1, GSK3B |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.377E-05 | 3.177E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.377E-05 | 3.177E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.389E-05 | 3.177E-03 | CYP1B1, GSK3B, MAPT, MCL1, NOX4, PTGS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 2.407E-05 | 3.177E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.377E-05 | 3.177E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.377E-05 | 3.177E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 2.623E-05 | 3.401E-03 | ALOX15, GSK3B, HIF1A, MAPT, NOX4, TNKS, TNKS2, TP53 |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 2.670E-05 | 3.440E-03 | ABCG2, ACHE, AR, FLT3, HIF1A, MAPT, MCL1, PTGS2, TP53, TTR, XDH |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.289E-05 | 4.093E-03 | ABCC1, ALOX15, SYK |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 3.368E-05 | 4.167E-03 | APEX1, CYP1A1, CYP1B1, CYP2D6, ESR2, GSK3B, MAOA, MCL1, NOX4, PKM, TP53 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.624E-05 | 4.409E-03 | CSNK2A1, HIF1A, MAPT |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.957E-05 | 4.708E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 4.212E-05 | 4.958E-03 | ALOX15, FLT3, GSK3B, HIF1A, MCL1, PTGS2, TP53 |
| BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 4.383E-05 | 5.103E-03 | ACHE, CFTR, GSK3B, HIF1A, PTGS2, SYK, TP53 |
| BP | GO:0051179; localization | GO:0060341; regulation of cellular localization | 5.231E-05 | 5.995E-03 | AR, CFTR, CSNK2A1, GSK3B, HIF1A, MAPT, PTGS2, SYK, TP53 |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 5.638E-05 | 6.361E-03 | ALOX15, PTGS2, SYK |
| CC | Unclassified; | GO:0043234; protein complex | 5.742E-05 | 6.445E-03 | APEX1, AR, CDK6, CFTR, CSNK2A1, ESR1, FLT3, GSK3B, HIF1A, MAPT, MCL1, POLB, PTGS2, SYK, TNKS, TP53, TTR |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 5.898E-05 | 6.552E-03 | APEX1, GSK3B, PKM, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 5.928E-05 | 6.552E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 6.422E-05 | 7.063E-03 | ALOX15, AR, FLT3, NOX4, SYK, THPO, XDH |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 6.538E-05 | 7.154E-03 | CYP19A1, CYP1A2, NOX4, XDH |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 7.122E-05 | 7.640E-03 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 8.289E-05 | 8.554E-03 | CYP1A1, CYP2D6 |
| MF | GO:0005488; binding | GO:0070324; thyroid hormone binding | 8.289E-05 | 8.554E-03 | PKM, TTR |
| MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 8.289E-05 | 8.554E-03 | ABCC1, ABCG2 |
| CC | GO:0043226; organelle | GO:0044454; nuclear chromosome part | 8.269E-05 | 8.554E-03 | APEX1, AR, CSNK2A1, ESR1, TNKS, TNKS2, TP53 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 8.552E-05 | 8.784E-03 | ALOX15, ESR1, GSK3B, MAPT, TP53 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 8.635E-05 | 8.827E-03 | AR, ESR1, GSK3B, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.381E-09 | 1.726E-07 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.294E-08 | 2.684E-06 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.946E-07 | 1.228E-05 | CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.072E-06 | 2.681E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.284E-07 | 1.651E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.024E-05 | 1.600E-04 | AR; GSK3B; CDK6; FLT3; PTGS2; HIF1A; TP53 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.661E-06 | 1.600E-04 | PKM; FLT3; TP53; HIF1A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 9.741E-06 | 1.600E-04 | MAOA; CYP2D6; CYP1A2; CYP3A4 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.203E-05 | 3.023E-04 | ABCC1; CDK6; CYP1B1; PTGS2; TP53; MCL1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.673E-05 | 4.867E-04 | POLB; CDK6; PKM; SYK; TP53 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.763E-05 | 7.627E-04 | PKM; MAOA; HSD17B1; CYP1A2; ALOX15; CYP1A1; PTGS2; CYP3A4; CYP19A1; XDH |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.589E-05 | 6.336E-04 | CYP2D6; MAOA; ALOX15; PTGS2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.074E-05 | 7.159E-04 | GSK3B; TP53; ESR1; HIF1A |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.399E-04 | 1.029E-03 | GSK3B; CDK6; CSNK2A1; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.419E-05 | 3.023E-04 | CYP1A2; ALOX15; CYP3A4 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 5.004E-04 | 2.979E-03 | GSK3B; CDK6; SYK; TP53; MCL1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.725E-04 | 2.328E-03 | GSK3B; ESR1; ESR2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 6.300E-04 | 3.424E-03 | GSK3B; SYK; CSNK2A1; TP53 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 8.590E-05 | 7.159E-04 | ABCC1; CFTR; ABCG2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.754E-04 | 1.913E-03 | CYP1A2; CYP1A1; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.933E-04 | 3.611E-03 | GSK3B; AR; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.575E-04 | 2.328E-03 | CYP3A4; CFTR; ABCG2 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 6.273E-04 | 3.424E-03 | CDK6; PTGS2; TP53 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 7.879E-04 | 3.940E-03 | SYK; CSNK2A1; PTGS2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.656E-03 | 1.186E-02 | GSK3B; CSNK2A1; TP53 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.806E-03 | 8.684E-03 | GSK3B; CDK6; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.197E-03 | 2.416E-02 | TP53; HIF1A; ESR1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.620E-03 | 1.925E-02 | GSK3B; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 5.339E-03 | 2.022E-02 | CDK6; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.339E-03 | 2.022E-02 | PTGS2; TSHR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 7.132E-03 | 2.416E-02 | CDK6; TP53 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.377E-02 | 3.913E-02 | POLB; GSK3B; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 6.508E-03 | 2.324E-02 | GSK3B; TP53 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 5.155E-03 | 2.022E-02 | GSK3B; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.346E-03 | 2.416E-02 | CDK6; TP53 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 8.459E-03 | 2.643E-02 | CDK6; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.924E-03 | 2.656E-02 | CDK6; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 8.924E-03 | 2.656E-02 | GSK3B; SYK |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.508E-03 | 2.324E-02 | ALOX15; PTGS2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.596E-02 | 4.432E-02 | ESR1; ESR2 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.633E-03 | 1.566E-02 | CYP3A4; XDH |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.276E-02 | 3.710E-02 | THPO; FLT3 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 8.005E-03 | 2.566E-02 | CDK6; TP53 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.883E-03 | 8.718E-03 | POLB; APEX1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.691E-05 | 4.195E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; SYK; TP53; FLT3; PKM |
| NA: NA | Menopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAOA; PTGS2; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; PTGS2; PTGS2; PTGS2; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; ABCC1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; HIF1A; SYK; TP53; FLT3; FLT3; ACHE; ESR1; ESR1; MCL1; PTGS2; CSNK2A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PTGS2; ABCC1; ABCC1 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |